p53 and survival in early onset breast cancer: Analysis of gene mutations, loss of heterozygosity and protein accumulation

European Journal of Cancer

Volumn 35, Issue 8, 1999, Pages 1202-1207

  Gentile, M ^b   Bergman Jungestrom M ^b   Olsen, K E ^a   Soderkvist P ^b   Wingren, S ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b NONE

Author keywords

Breast cancer; Early onset; p53 protein; Prognosis; TP53 gene; Young age; Zinc binding domain

Indexed keywords

PROTEIN; PROTEIN P53;

ADULT; ARTICLE; BIOACCUMULATION; BREAST CANCER; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; SURVIVAL;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032812896     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00121-5     Document Type: Article

References (36)

1. Adami H.O., Malker B., Holmberg L., Person I., Stone B. The relation between survival and age at diagnosis in breast cancer. N. Engl. J. Med. 315:1986;559-563.
2. Walker R.A., Lees E., Webb M.B., Dearing S.J. Breast carcinomas occurring in young women (<35) are different. Br. J. Cancer. 74:1996;1796-1800.
3. Rochefordiere A., Asselain B., Campana F.et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 341:1993;1039-1043.
4. Albain K., Allred C., Clark G. Breast cancer outcome and predictors of outcome. are there age differentials? J. Natl. Cancer Inst. 16:1994;35-42.
5. Bonnier P., Romain S., Charpain C.et al. Age as prognostic factor in breast cancer. relationship to patologic and biologic features Int. J. Cancer. 62:1995;138-144.
6. Nixon B., Neuberg D., Hayes D.et al. Relationship of patient age to pathologic features of the tumour and prognosis for patients with stage I or II breast cancer. J. Clin. Oncol. 12:1994;888-894.
7. Chung M., Chang H., Bland K., Wanebo H. Younger women with breast cancer have a poorer prognosis than older women. Cancer. 77:1996;97-103.
8. Kollias J., Elston C.W., Ellis I.O., Robertson J.F., Blamey R.W. Early onset breast cancerhistopathological and prognostic considerations. Br. J. Cancer. 75:1997;1318-1323.
9. Cho Y., Gorina S., Jeffrey P., Pavletich N. Crystal structure of a p53 tumour suppressor-DNA complex. understanding tumorigenic mutations Science. 265:1994;346-355.
10. Hollstein M., Rice K., Greenblatt M.S.et al. Data base of p53 gene somatic mutations in human tumours and cell lines. Nucleic Acids Res. 22:1994;3551-3555.
11. Allred D.C., Clarke G.M., Elledge R.et al. Association of protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 85:1993;200-206.
12. Stenmark-Askmalm M., Stål O., Sullivan S.et al. Cellular accumulation of the p53 protein. an independent prognostic factor in stage II breast cancer Eur. J. Cancer. 30A:1994;175-180.
13. Seshadri R., Leong A., McCaul K., Firgaira F., Setlur V., Horsfall D. Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis. Int. J. Cancer. 69:1996;135-141.
14. Elledge R., Allred C. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res. Treat. 32:1994;39-47.
15. Hartmann A., Blazyk H., Kovach J., Sommer S. The molecular epidemiology of p53 gene mutations in breast cancer. Trends Genet. 13:1997;27-33.
16. Thor A., Moore II D., Edgerton S.et al. Accumulation of p53 tumor suppressor gene protein. an independent marker of prognosis in breast cancers J. Natl. Cancer Inst. 84:1992;845-855.
17. Berns E.M.J.J., Klijn J., Smid M.et al. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosom. Cancer. 16:1996;170-179.
18. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis Cancer Res. 54:1994;4855-4878.
19. Borresen A.L., Andersen T.I., Eyfjord J.et al. TP53 mutations and breast cancer prognosis. particularly poor survival rates for cases with mutations in the zinc-binding domains Genes Chromosom. Cancer. 14:1995;71-75.
20. Berns E.M.J.J., van Staveren I.L., Look M.P., Smid M., Klijn J.G.M., Foekens J.A. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br. J. Cancer. 77:1998;1130-1136.
21. Aas T., Börresen A.L., Geisler S.et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2:1996;811-814.
22. Caleffi M., Teague M., Jensen R., Vnencak-Jones C., Dupont W., Parl F. P53 gene mutations and steroid receptor status in breast cancer. Cancer. 73:1994;2147-2156.
23. Deng G., Chen L.C., Schott D.et al. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res. 54:1994;499-505.
24. Shibata D., Brynes R.K., Nathwani B., Kwok S., Sninsky J., Arnheim N. Human immunodeficiency viral DNA is readily found in lymph node biopsies from seropositive individuals. Analysis of fixed tissue using the polymerase chain reaction. Am. J. Pathol. 135:1989;697-702.
25. Porter P., Malone K., Heagerty P.et al. Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 3:1997;222-225.
26. Bertheau P., Steinberg S., Merino M. C-erbB-2, p53 and nm23 gene product expression in breast cancer in young women. immunohistochemical analysis and clinicopathologic correlation Hum. Pathol. 29:1998;323-329.
27. Clahsen P., van de Velde C., Duval C.et al. P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. Oncol. 16:1998;470-479.
28. Bergh J., Norberg T., Sjögren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1:1995;1029-1034.
29. Stål O., Stenmark-Askmalm M., Wingren S.et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol. 34:1995;767-770.
30. Andersen T.I., Gaustad A., Ottestad L.et al. Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. Genes Chromosom. Cancer. 4:1992;113-121.
31. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
32. Fuchs S.Y., Adler V., Bushman T.et al. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 1:1998;2658-2663.
33. Fuchs S.Y., Adler V., Buschman T., Wu X., Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene. 12:1998;2543-2547.
34. Spataro V., Norbury C., Harris A.L. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer. 77:1998;448-455.
35. Cho Y., Gorina S., Jeffrey P.D., Pavetich N.P. Crystal structure of a p53 tumor suppressor-DNA complex. understanding tumorigenic mutations Science. 265:1994;346-355.
36. Arrowsmith C.H., Morin P. New insights into p53 function from structural studies. Oncogene. 12:1996;1379-1385.